- Home
- QNRX vs BFRG Comparison
QNRX vs BFRG Comparison
Compare QNRX & BFRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | QNRX | BFRG |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.7M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | QNRX | BFRG |
|---|---|---|
| Price | $7.06 | $0.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 901.6K | 88.5K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.88 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,670.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 79.49 |
| 52 Week Low | $3.25 | $0.43 |
| 52 Week High | $41.80 | $2.04 |
Technical Indicators
Market Signals| Indicator | QNRX | BFRG |
|---|---|---|
| Relative Strength Index (RSI) | 67.72 | 36.50 |
| Support Level | $7.00 | $0.43 |
| Resistance Level | $8.25 | $0.69 |
| Average True Range (ATR) | 0.52 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 76.21 | 18.86 |
Price Performance
Historical ComparisonAbout QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About BFRG Bullfrog AI Holdings Inc.
Bullfrog AI Holdings Inc is a clinical-phase Biotechnology company using machine learning to advance medicine and improve human health. It uses artificial intelligence and machine learning to advance medicines for both internal and external projects. The Company is focused specifically on advance artificial intelligence and machine learning (AI/ML)- driven analysis of complex datasets in medicine and healthcare. The Company's objective is to use its AI/ML platform to provide a precision-medicine approach to drug-asset enablement through external partnerships and selective internal development.